Dara Azar
Stock Analyst at Stifel Nicolaus
(2.57)
# 2,942
Out of 5,044 analysts
22
Total ratings
61.5%
Success rate
5.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Reiterated: Hold | $24 | $19.55 | +22.76% | 2 | Oct 6, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.52 | +155.68% | 1 | Oct 1, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | n/a | $17.59 | - | 8 | Sep 29, 2026 | |
| INBX Inhibrx Biosciences | Reiterated: Buy | $325 | $95.01 | +242.07% | 7 | Aug 21, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $82 | $40.98 | +100.10% | 4 | Aug 13, 2026 |
Immunome
Oct 6, 2026
Reiterated: Hold
Price Target: $24
Current: $19.55
Upside: +22.76%
Whitehawk Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.52
Upside: +155.68%
Summit Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $17.59
Upside: -
Inhibrx Biosciences
Aug 21, 2026
Reiterated: Buy
Price Target: $325
Current: $95.01
Upside: +242.07%
Enliven Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $82
Current: $40.98
Upside: +100.10%